Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹4,576.95Prev. Close
₹4,571.45Turnover(Lac.)
₹26,142.25Day's High
₹4,595.05Day's Low
₹4,50552 Week's High
₹4,648.4552 Week's Low
₹3,295.3Book Value
₹537.97Face Value
₹2Mkt Cap (₹ Cr.)
1,21,031.11P/E
76.69EPS
59.37Divi. Yield
0.663 Jul 2023
12:00 AM
AGM
Announcement Date: 03 Jul, 2023
15 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
20 May 2023
12:00 AM
Dividend
Dividend Amount: 30
Record Date: 11 Aug, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 53.09 | 53.09 | 53.09 | 53.09 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 12,652.33 | 11,638.26 | 9,218.48 | 7,263.6 |
Net Worth | 12,705.42 | 11,691.35 | 9,271.57 | 7,316.69 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 8,879.82 | 6,798.61 | 5,310.57 | 3,815.94 |
yoy growth (%) | 30.61 | 28.02 | 39.16 | -5.16 |
Raw materials | -2,989.8 | -2,265.5 | -2,088.56 | -1,504.9 |
As % of sales | 33.66 | 33.32 | 39.32 | 39.43 |
Employee costs | -926.55 | -808.68 | -608.36 | -446.27 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 3,676.52 | 2,627.87 | 1,813.29 | 1,219.36 |
Depreciation | -310.55 | -254.65 | -185.95 | -142.42 |
Tax paid | -727.98 | -673.15 | -440.58 | -349.78 |
Working capital | 2,090.79 | 2,216.26 | 733.27 | 298.91 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 30.61 | 28.02 | 39.16 | -5.16 |
Op profit growth | 37.42 | 55.37 | 45.16 | -13.01 |
EBIT growth | 39.89 | 44.47 | 49.04 | -12.21 |
Net profit growth | 50.84 | 42.39 | 57.85 | -17.43 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 7,845 | 7,767 | 8,959.83 | 6,969.4 | 5,394.42 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 7,845 | 7,767 | 8,959.83 | 6,969.4 | 5,394.42 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 339 | 345 | 113.87 | 62.56 | 189.63 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,529.65 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,570.7 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,484.5 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,106.1 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,484.75 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Murali K Divi
Executive Director
N V Ramana
Whole Time Director (Projects)
Madhusudana Rao Divi
Whole Time Director & CEO
Kiran S Divi
Independent Director
G Suresh Kumar
Independent Director
Ranga Rao Ravipati
Independent Director
K V K Seshavataram
Chairman(Non Exe)&Director(Ind
Ramesh B V Nimmagadda
Whole Time Director -Commercia
Nilima Motaparti
Independent Director
S Ganapaty
Independent Director
Sunaina Singh
Independent Director
Kosaraju Veerayya Chowdary
Company Sec. & Compli. Officer
Satish Choudhury
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Divis Laboratories Ltd
Summary
Divis Laboratories Ltd. is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of the worlds largest API companies, with two manufacturing units and a market presence across 100 countries. It is engaged in the manufacture of Active Pharmaceutical ingredients (APIs), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. It is among the largest pharmaceutical companies in India with a portfolio of approx. 160 products across diverse therapeutic areas. Presently, it has 6 manufacturing facilities and market presence across several countries. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divis Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale proc
Read More
What is the Divis Laboratories Ltd share price today?
The Divis Laboratories Ltd shares price on nse is Rs.₹4559.15 today.
What is the Market Cap of Divis Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Divis Laboratories Ltd is ₹121031.11 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Divis Laboratories Ltd?
The PE and PB ratios of Divis Laboratories Ltd is 76.69 and 8.96 as of 03 Jul ‘24
What is the 52 Week High and Low of Divis Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Divis Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Divis Laboratories Ltd is ₹3295.3 and ₹4648.45 as of 03 Jul ‘24
What is the CAGR of Divis Laboratories Ltd?
Divis Laboratories Ltd's CAGR for 5 Years at 23.10%, 3 Years at 0.38%, 1 Year at 27.43%, 6 Month at 13.44%, 3 Month at 26.20% and 1 Month at 5.77%.
What is the shareholding pattern of Divis Laboratories Ltd?
The shareholding pattern of Divis Laboratories Ltd is as follows:
Promoters - 51.92 %
Institutions - 36.89 %
Public - 11.19 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
